LPL Financial LLC Purchases 57,305 Shares of Recursion Pharmaceuticals, Inc. $RXRX

LPL Financial LLC grew its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 15.6% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 425,090 shares of the company’s stock after purchasing an additional 57,305 shares during the period. LPL Financial LLC owned about 0.11% of Recursion Pharmaceuticals worth $2,249,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC increased its holdings in Recursion Pharmaceuticals by 39.0% during the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after buying an additional 2,026 shares during the last quarter. NewEdge Advisors LLC increased its holdings in Recursion Pharmaceuticals by 43.7% during the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company’s stock worth $53,000 after buying an additional 2,387 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Recursion Pharmaceuticals during the fourth quarter worth $54,000. San Luis Wealth Advisors LLC acquired a new position in Recursion Pharmaceuticals during the first quarter worth $54,000. Finally, ADG Wealth Management Group LLC acquired a new position in Recursion Pharmaceuticals during the first quarter worth $55,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Trading Down 4.3%

Shares of Recursion Pharmaceuticals stock opened at $5.52 on Tuesday. Recursion Pharmaceuticals, Inc. has a 1 year low of $3.79 and a 1 year high of $12.36. The firm has a market cap of $2.40 billion, a PE ratio of -3.10 and a beta of 0.93. The stock has a fifty day moving average price of $5.49 and a 200-day moving average price of $5.81. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%. The firm had revenue of $19.10 million during the quarter, compared to analysts’ expectations of $15.38 million. During the same period last year, the business posted ($0.40) EPS. The company’s revenue was up 33.3% compared to the same quarter last year. Equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on RXRX shares. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Tuesday, July 8th. Morgan Stanley started coverage on shares of Recursion Pharmaceuticals in a report on Thursday, July 3rd. They issued an “equal weight” rating and a $5.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $7.00.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.